TriSalus launches new infusion system designed for larger embolic particles

TriSalus Life Sciences has introduced the TriNav XP Infusion System, the latest addition to its pressure-enabled drug delivery platform aimed at improving treatment of solid tumors. The device is engineered to enhance therapy delivery in a wide range of vascular environments and to accommodate larger embolic particles than previous models.

The new system builds on the company’s existing TriNav platform but is specifically designed to handle embolic beads up to 700 micrometers. It also features a more flexible distal tip for improved navigation and comes in 130-cm and 150-cm lengths. The catheter is recommended for use in vessels measuring 1.5 mm to 3.5 mm.

TriNav XP incorporates the company’s SmartValve technology, which has demonstrated in multiple studies the ability to deliver therapy deeper into target tissue while reducing unintended delivery to surrounding healthy areas.

“At TriSalus, our goal is to empower physicians with tools that deliver therapy more effectively and consistently,” said Mary Szela, CEO and president of TriSalus Life Sciences. “The TriNav XP Infusion System extends the reach of our Pressure-Enabled Drug Delivery approach with our SmartValve Technology, giving clinicians greater flexibility to treat patients in a range of embolization procedures.”

Advances in interventional oncology and drug delivery

Interventional oncology continues to evolve rapidly as clinicians look for more precise, targeted ways to treat solid tumors with fewer systemic side effects. Catheter-based drug delivery platforms—particularly those capable of navigating complex vasculature—have become central to efforts to improve tumor response rates and spare healthy tissues.

One major area of advancement is the development of technologies that enable greater control over pressure and flow during infusion. Newer systems are designed to push therapeutic agents deeper into tumor beds while minimizing reflux, a long-standing challenge in embolization procedures. By altering local hemodynamics, these devices can improve penetration of chemotherapeutics or immunotherapies and reduce exposure to non-target tissues.

Another trend is the ability to work with a broader range of embolic particle sizes. Larger particles are increasingly used in specific embolization strategies, particularly when greater occlusion or more sustained drug delivery is required. Devices that maintain stability and accuracy while delivering these larger beads allow physicians to tailor treatments more precisely to individual tumor characteristics.

Improvements in catheter flexibility and trackability are also reshaping interventional oncology. Tumors located in small or tortuous vessels can be difficult to reach with traditional devices. Modern microcatheters with enhanced navigation features help interventional radiologists access challenging anatomy, which is critical for both drug delivery and combination-treatment approaches.

Finally, integration with imaging and procedural planning tools continues to expand. Systems that work seamlessly with high-resolution imaging can help clinicians assess blood flow dynamics in real time and adjust treatment accordingly. As interventional oncology moves toward more personalized, anatomy-specific treatment, these combined advances are helping expand the number of patients who may benefit from catheter-delivered therapies.